Greenwich Lifesciences

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors had a field day with Greenwich LifeSciences on Wednesday after the tiny biotech company skyrocketed as much as 2,941% on encouraging phase 2b data for its breast cancer immunotherapy treatment, GP2. On Tuesday, shares of Greenwich LifeSciences closed at $5.20. The stock proceeded to trade as high as $158.07 just before 3 p.m. on Wednesday. The market value of Greenwich soared to more than $1.5 billion at intraday highs, up from just $62 million the prior day.

Greenwich LifeSciences rockets 2,941% in a single day after encouraging phase 2 data on breast cancer treatment (GLSI)

GLSI stock is soaring Wednesday after Greenwich LifeSciences shared promising results from its breast cancer immunothrapy. The post GLSI Stock: Why Greenwich LifeSciences Is Up 2,000% Today appeared first on InvestorPlace.

GLSI Stock: Why Greenwich LifeSciences Is Up 2,000% Today

Shares of Greenwich LifeSciences Inc. blasted 2,399.3% higher in very active and volatile afternoon trading Wednesday, after the Texas-based biopharmaceutical company displayed upbeat results of a Phase IIb trial for its breast cancer treatment. The stock, which has been halted no less than 20 times for volatility, was easily the biggest gainer trading on major U.S. exchanges, while trading volume of 15.9 million shares was many multiples of the full-day average of about 22,000 shares.

Greenwich LifeScience stock skyrockets more than 2,000% after upbeat data on breast cancer treatment

Shares of Greenwich LifeSciences Inc. were launched to a more than fourfold gain in very active midday trading Wednesday, after the Texas-based biopharmaceutical company displayed upbeat results of a Phase IIb trial for its breast cancer treatment. The stock's 345.3% gain, prior to a trading halt for volatility, made it the biggest gainer trading on major U.S. exchanges, while trading volume of 8.5 million shares was many multiples of the full-day average of about 22,000 shares.

Greenwich LifeScience skyrockets more than fourfold after upbeat data on breast cancer treatment

Greenwich LifeSciences's (NASDAQ: GLSI) stock has been rising Wednesday, up 350.11% to a price of $19.85. Wednesday the stock has been traded at a volume of 2.32 million, about 10387.18% of its recent 30-day volume average of 22.31 thousand.

Why Is It Moving? Looking At Greenwich LifeSciences's Price Action Today

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer

Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces New Manufacturing Agreement for its Planned Phase III Clinical Trial and Enters into Lease for Office and Lab Space

Greenwich LifeSciences Announces New Manufacturing Agreement for its Planned Phase III Clinical Trial and Enters into Lease for Office and Lab Space

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at the Annual LD Micro Main Event

Greenwich LifeSciences to Present at the Annual LD Micro Main Event

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Second Publication and Poster Presentation of Phase III Clinical Trial of Breakthrough for Recurring Breast Cancer

Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Publication of Positive Phase IIb Clinical Trial Data for GP2 for the Prevention of Recurring Breast Cancer

Greenwich LifeSciences Announces Publication of Positive Phase IIb Clinical Trial Data for GP2, Its Lead Drug Candidate for the Prevention of Recurring Breast Cancer

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial

Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. to Participate at Texas Life Sciences Forum Investor Conference

Greenwich LifeSciences, Inc. to Participate at Texas Life Sciences Forum Investor Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Acceptance of Two Abstracts at Upcoming Major Breast Cancer Conference

Greenwich LifeSciences, Inc. Announces Acceptance of Two Abstracts at Upcoming Major Breast Cancer Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Completion of Manufacturing of Drug for its Planned Phase III Clinical Trial

Greenwich LifeSciences, Inc. Announces Completion of Manufacturing of Drug for its Planned Phase III Clinical Trial

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Closing of Initial Public Offering

Greenwich LifeSciences, Inc. Announces Closing of Initial Public Offering

Amesite Operating

Bentley Systems

Corsair Gaming

GoodRx Holdings

Graybug Vision

Laird Superfood

PMV Pharmaceuticals

Prelude Therapeutics

Array Technologies

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the pricing of its initial public offering of 1,260,870 shares of its common stock at a public offering price of $5.75 per share for gross proceeds of $7,250,002, before deducting offering expenses.

Greenwich LifeSciences, Inc. Announces Pricing of Initial Public Offering

News for Greenwich Lifesciences Stock (GLSI)